Press Release

Thrifty White Takes the Lead in Re-Launching the Personalized-Medication Adherence and Persistence Program (P-MAPP)

The P-MAPP, supported by MediMergent, FDA and multiple healthcare stakeholders, partner with pharmacists to improve outcomes for patients with Type 2 Diabetes

October 14, 2020

Plymouth, Minnesota –

Robert Narveson, Chairman, President/CEO of Thrifty White Pharmacy addressed the P-MAPP Consortium Advisory Board regarding the role of his pharmacies in the P-MAPP.” Our business model aligns with the P-MAPP; listening to the Voice of the Patient and bringing the pharmacist out from behind the counter and engaging with patients. We are thrilled to be part of this program and demonstrate what pharmacists can do not only to impact improvement in health outcomes but to participate in broader research endeavors. As we reactivate patient enrollment, the realities of COVID-19 require that we conduct our Motivational Interviews remotely using video/audio conferencing. We are still engaging with patients and helping them to identify options for healthier outcomes.”

The P-MAPP combines patient engagement, digital technologies and predictive analytics to define personalized strategies to improve medication adherence and persistence in patients with Type 2 diabetes. It is the first all pharmacy-based program supported by representatives from multiple stakeholder groups including regulators, prescribers, pharmacists, pharmaceutical companies, health insurers, professional organizations, medical device companies and academia. Thrifty White Pharmacy, the first pharmacy chain to launch the P-MAPP, kicks off reactivating patient enrollment following the COVID-19 lock-down.

Using the MediMergent digital platform, the P-MAPP collects data from real-world sources including patient-reported experience surveys, medical records, pharmacy fill/refill data, claims, and wearable devices. Based on a well-established behavioral model that identifies barriers to medication adherence, app-based surveys are completed by patients. Data are transferred, near-real time, to the enrolling pharmacists who schedule private counseling sessions with their patients to review the data and generate strategies to address drivers of non-adherence. Patients are followed for 12-months.

Norman Stockbridge, MD, PhD, Director, Division of Cardiology and Nephrology, FDA Center for Drug Evaluation and Research stated “reaching out to patients in multifaceted ways is even more critical today under the global COVID-19 pandemic than when the program launched in 2019. Patients are in critical need of outreach by healthcare providers, especially prescribers and pharmacists, to ensure that they are receiving appropriate medical attention and are following their medical regimens. The P-MAPP provides a structured pathway for such engagement.”

Greg Simon, President of MediMergent said “we talk about the patient being the most underutilized resource in healthcare yet we are organized to get information about the patient without focusing on getting information with the patient. The P-MAPP leverages the strengths of pharmacists to engage directly with patients, identify individual drivers of nonadherence behaviors and together generate personalized strategies to improve adherence and ultimately, health outcomes”.

About Thrifty White

Headquartered in Plymouth, MN, Thrifty White Pharmacy is a technology enabled healthcare services company focused on utilizing patient engagement to improve outcomes and reduce the cost of care. By leveraging the unique capabilities of pharmacists, combined with focused technology and clinical care plans, the company creates better patient experiences and improved patient outcomes. Thrifty White Pharmacy has been recognized by multiple organizations as a leading “Pharmacy Innovator” for its efforts to continually move the practice of pharmacy forward.

About MediMergent, LLC

MediMergent is a leading Real-World Data and Evidence (RWD/RWE) company combining patient engagement, digital technologies, and predictive analytics to collect, integrate and interrogate Real-World Data from the context of the patient. The Company’s digital platform leverages the power of the patient’s voice to provide accurate, reliable, and comprehensive data with the goal of improving health outcomes and compliance to treatment. MediMergent delivers the Voice of the Patient through a suite of digital applications and proprietary surveys that engage directly with the patient. These data are combined with advanced technologies including AI, ML, and predictive analytics to collect, integrate and analyze Real-World Data that brings real-world impact to Real-World Evidence.

To learn more about MediMergent’s Real-World Evidence solutions, please contact them at


MediMergent Media
Jessica Beote
Matter Communications